In 2025, the company reported a strong +17.08% YoY revenue growth, largely driven by its core therapies: Jardiance ($10.33B) continues to lead as a blockbuster across diabetes, heart failure, and kidney disease, Ofev ($4.49B) remains a key growth driver in pulmonary fibrosis, while Trajenta ($1.72B) continues to contribute despite a mature lifecycle - highlighting a portfolio balancing high-growth and established assets
Whrend stationre Verkaufsstellen oft eine persnlichere Beratung bieten, ist die Auswahl online deutlich grer
Expired Semaglutide : Avoid using expired Semaglutide, as it may lose effectiveness and pose health risks
When you're trying to isolate the effects of a specific compound, you simply cannot afford the uncertainty that comes with a low-quality source
Knowing how to transition between different semaglutide formats without disrupting your protocol is a practical skill that comes up more often than you might expect
developed tissue specific KOs of HSL in adipocytes and liver